PE20090075A1 - Combinacion de antagonista del receptor de progesterona con un agonista y un antagonista de la hormona liberadora de hormona luteinizante para usar en enfermedades mediadas por brca - Google Patents
Combinacion de antagonista del receptor de progesterona con un agonista y un antagonista de la hormona liberadora de hormona luteinizante para usar en enfermedades mediadas por brcaInfo
- Publication number
- PE20090075A1 PE20090075A1 PE2008000689A PE2008000689A PE20090075A1 PE 20090075 A1 PE20090075 A1 PE 20090075A1 PE 2008000689 A PE2008000689 A PE 2008000689A PE 2008000689 A PE2008000689 A PE 2008000689A PE 20090075 A1 PE20090075 A1 PE 20090075A1
- Authority
- PE
- Peru
- Prior art keywords
- antagonist
- combination
- progesterone receptor
- brca
- mediated diseases
- Prior art date
Links
- 108700012941 GNRH1 Proteins 0.000 title abstract 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 title abstract 2
- 229940123788 Progesterone receptor antagonist Drugs 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- -1 4-ACETYLPHENYL Chemical class 0.000 abstract 2
- 102000036365 BRCA1 Human genes 0.000 abstract 1
- 108700020463 BRCA1 Proteins 0.000 abstract 1
- 101150072950 BRCA1 gene Proteins 0.000 abstract 1
- 102000052609 BRCA2 Human genes 0.000 abstract 1
- 108700020462 BRCA2 Proteins 0.000 abstract 1
- 101150008921 Brca2 gene Proteins 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 abstract 1
- 108010069236 Goserelin Proteins 0.000 abstract 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 abstract 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 abstract 1
- 108010021717 Nafarelin Proteins 0.000 abstract 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 229960001442 gonadorelin Drugs 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 229960002913 goserelin Drugs 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 abstract 1
- 229960002333 nafarelin Drugs 0.000 abstract 1
- 239000006187 pill Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 abstract 1
- 229960004824 triptorelin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
SE REFIERE A UNA COMBINACION FARMACEUTICA QUE CONTIENE: A) UN ANTAGONISTA DEL RECEPTOR DE PROGESTERONA TAL COMO 11 -(4-ACETILFENIL)-17 -HIDROXI-17a-(1,1,2,2,2-PENTAFLUOROETIL)-ESTRA-4,9-DIEN-3-ONA QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,1MG A 150MG; Y B) UN AGONISTA O ANTAGONISTA DE LA HORMONA LIBERADORA DE HORMONA LUTEINIZANTE TAL COMO GONADORELINA, GOSERELINA, TRIPTORELINA, NAFARELINA, ENTRE OTROS, QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,1MG A 200MG. DICHA COMBINACION SE ENCUENTRA EN FORMA DE TABLETAS, PILDORAS, CAPSULAS DE GEL, IMPLANTES, ENTRE OTROS, SIENDO UTIL EN EL TRATAMIENTO DE CANCER DE MAMA MEDIADO POR BRCA1 O BRCA2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07090084 | 2007-04-23 | ||
| US91438307P | 2007-04-27 | 2007-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090075A1 true PE20090075A1 (es) | 2009-04-24 |
Family
ID=39872872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000689A PE20090075A1 (es) | 2007-04-23 | 2008-04-22 | Combinacion de antagonista del receptor de progesterona con un agonista y un antagonista de la hormona liberadora de hormona luteinizante para usar en enfermedades mediadas por brca |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080261933A1 (es) |
| EP (1) | EP2148682A1 (es) |
| JP (1) | JP2010524996A (es) |
| AR (1) | AR066233A1 (es) |
| CA (1) | CA2683517A1 (es) |
| CL (1) | CL2008001149A1 (es) |
| PA (1) | PA8777601A1 (es) |
| PE (1) | PE20090075A1 (es) |
| TW (1) | TW200902029A (es) |
| UY (1) | UY31042A1 (es) |
| WO (1) | WO2008128786A1 (es) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5372996A (en) * | 1989-03-10 | 1994-12-13 | Endorecherche, Inc. | Method of treatment of androgen-related diseases |
| TW274552B (es) * | 1992-05-26 | 1996-04-21 | Hoechst Ag | |
| NZ334236A (en) * | 1996-08-30 | 2000-06-23 | Peptech Ltd | Composition comprising GnRH, lecithin and stearin |
| US8052982B2 (en) * | 1998-07-20 | 2011-11-08 | Peptech Animal Health Pty Limited | Bioimplant formulation comprising lecithin and stearin |
| CN1243543C (zh) * | 1998-07-20 | 2006-03-01 | 派普泰克有限公司 | 生物植入物配方 |
| DE10051609A1 (de) * | 2000-10-18 | 2002-05-02 | Schering Ag | Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen |
| SI1326617T1 (sl) * | 2000-10-18 | 2007-02-28 | Schering Ag | Uporaba 11 beta-(4-acetilfenil)-17 beta-hidroksi-17 alfa-(1,1,2,2,2-pentafluoroetil)estra-4,9-dien-3-ona za pripravo zdravila za zdravljenje raka dojk, raka jajcnikov, endometrijskega raka, mieloma in meningioma |
| UY26966A1 (es) * | 2000-10-18 | 2002-06-20 | Schering Ag | Uso de antiprogestinas para la inducción de apoptosis en una célula |
| KR20030051828A (ko) * | 2000-11-16 | 2003-06-25 | 파마시아 앤 업존 컴파니 | 에스트로겐 의존성 질환의 병용 치료법 |
| US20030013694A1 (en) * | 2001-05-25 | 2003-01-16 | Jens Hoffmann | Use and compositions of antiprogestins for treatment of prostate diseases |
| US20040043938A1 (en) * | 2001-11-06 | 2004-03-04 | Dinesh Purandare | Combination therapy for estrogen-dependent disorders |
| GB0307777D0 (en) * | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
-
2008
- 2008-04-21 US US12/106,566 patent/US20080261933A1/en not_active Abandoned
- 2008-04-21 WO PCT/EP2008/003328 patent/WO2008128786A1/en not_active Ceased
- 2008-04-21 EP EP08735385A patent/EP2148682A1/en not_active Withdrawn
- 2008-04-21 JP JP2010504549A patent/JP2010524996A/ja active Pending
- 2008-04-21 CA CA002683517A patent/CA2683517A1/en not_active Abandoned
- 2008-04-22 PE PE2008000689A patent/PE20090075A1/es not_active Application Discontinuation
- 2008-04-22 PA PA20088777601A patent/PA8777601A1/es unknown
- 2008-04-22 AR ARP080101669A patent/AR066233A1/es unknown
- 2008-04-22 UY UY31042A patent/UY31042A1/es not_active Application Discontinuation
- 2008-04-22 TW TW097114712A patent/TW200902029A/zh unknown
- 2008-04-22 CL CL2008001149A patent/CL2008001149A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010524996A (ja) | 2010-07-22 |
| CA2683517A1 (en) | 2008-10-30 |
| US20080261933A1 (en) | 2008-10-23 |
| PA8777601A1 (es) | 2008-11-19 |
| TW200902029A (en) | 2009-01-16 |
| AR066233A1 (es) | 2009-08-05 |
| EP2148682A1 (en) | 2010-02-03 |
| UY31042A1 (es) | 2009-01-30 |
| WO2008128786A1 (en) | 2008-10-30 |
| CL2008001149A1 (es) | 2008-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099830A (es) | Inhalador de polvos | |
| MX2010009447A (es) | Uso de antagonistas de lhrh a dosis no castrantes. | |
| GT200600445A (es) | Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo. | |
| EA201201403A1 (ru) | Очень низкодозированные твердые пероральные лекарственные формы для гзт | |
| UY33470A (es) | Derivados de 6,7-dihidro-5h-benzo[7]anulenos, métodos para su preparación, preparaciones farmacéuticas que los contienen y su uso para la preparación de medicamentos | |
| CO6280466A2 (es) | Forma de dosificacion farmaceutica de liberacion controlada | |
| GT201200012A (es) | Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimiento para su preparacion y su uso para el tratamiento de enfermedades | |
| PE20211588A1 (es) | Compuestos y sus usos para aliviar sintomas asociados a la menopausia | |
| BR112015018357A2 (pt) | dosador para um medicamento | |
| NI201700173A (es) | Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso | |
| UY36202A (es) | Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer | |
| PE20031047A1 (es) | Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama | |
| PE20121177A1 (es) | Fulvestrant en una dosis de 500 mg para el tratamiento del cancer de mama avanzado | |
| PE20090075A1 (es) | Combinacion de antagonista del receptor de progesterona con un agonista y un antagonista de la hormona liberadora de hormona luteinizante para usar en enfermedades mediadas por brca | |
| AR065971A1 (es) | Nuevo regimen de drosperinona/17beta-estradiol, producto farmaceutica combinado y conjunto de elementos (kit) para su aplicacion | |
| AR044450A1 (es) | Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas | |
| MX363979B (es) | Forma de dosificacion de un antagonista del receptor de progesterona. | |
| RU2020100230A (ru) | Лечение депрессии антагонистами nmda и антагонистами d2/5-ht2a или селективными антагонистами 5-нт2a | |
| ES2608816T3 (es) | Composición farmacéutica oral de desmopresina | |
| PE20090734A1 (es) | Combinacion de antagonista del receptor de progesterona con antiestrogenos no esteroidales | |
| DOP2007000122A (es) | Forma farmacologica peroral para anticoncepcion | |
| AR067699A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiandrogenico, un agente estrogenico esteroidico sintetico y agentes vitaminicos, util para el control y tratamiento del acne tardio en la mujer | |
| AR049220A1 (es) | Uso de 7-ter-butoxiiminometilcamptotecina en la preparacion de un medicamento util para el tratamiento de neoplasmas uterinos | |
| PA8777501A1 (es) | Combinación de antagonista del receptor de progesterona con antiestrógenos no esteroidales para usar en enfermedades mediadas por brca | |
| EA201590936A1 (ru) | Композиция левоноргестрела для оптимальной пероральной контрацепции с определенным содержанием левоноргестрела, режим дозирования и фармацевтический препарат |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |